Metastatic RCC earlier treated with the cytokines interferon alpha (IFNα) or interleukin 2 (IL-2) demonstrated low rates of efficacy along with severe infusion-related adverse reactions.[18] A newer therapeutic modality in these patients is now available as receptor tyrosine kinase (RTK) inhibitors. The gene discussed is NTRK1; the disease is renal cell carcinoma.